eligibility_summary
Include: 1–18 yrs with R/R CD19+/CD22+ B‑ALL after/intolerant to all standard therapies, no curative option, PB tumor ≥60% or severe cytopenia blocking autologous collection, ECOG 0–2, survival ≥60 d, DSA‑neg HLA‑matched/haplo donor, consent. Exclude: prior HSCT, serious CNS/cardiac/respiratory disease, other malignancy, DIC, renal ≥1.5×ULN, active infection/sepsis, uncontrolled DM, severe psych illness, significant non‑CNS‑ALL brain lesion, prior organ transplant, +hCG, HBV/HCV/HIV/syphilis, no donor.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: donor-derived (allogeneic) CAR-T cell therapy targeting CD19 to bridge an allogeneic hematopoietic stem cell transplant (allo-HSCT), followed by sequential donor-derived CD22 CAR-T cells, allo-HSCT (cell therapy) for hematopoietic reconstitution and graft-versus-leukemia. Type/mechanism: gene-modified cellular immunotherapies (CAR-T) whose scFv-based receptors bind CD19 or CD22 on B cells, triggering T-cell activation, cytokine release, and cytolytic killing, sequential dual-antigen targeting aims to curb antigen-loss relapse post-transplant. Cells/pathways targeted: leukemic B-cell precursors expressing CD19 and CD22 (B-lineage antigens linked to BCR signaling), plus allo-HSCT–mediated graft-versus-leukemia.